The PI3K signaling pathway regulates cell growth and movement and is heavily mutated in cancer. Class I PI3Ks synthesize the lipid messenger PI(3,4,5)P3. PI(3,4,5)P3 can be dephosphorylated by 3- or 5-phosphatases, the latter producing PI(3,4)P2. The PTEN tumor suppressor is thought to function primarily as a PI(3,4,5)P3 3-phosphatase, limiting activation of this pathway. Here we show that PTEN also functions as a PI(3,4)P2 3-phosphatase, both in vitro and in vivo. PTEN is a major PI(3,4)P2 phosphatase in Mcf10a cytosol, and loss of PTEN and INPP4B, a known PI(3,4)P2 4-phosphatase, leads to synergistic accumulation of PI(3,4)P2, which correlated with increased invadopodia in epidermal growth factor (EGF)-stimulated cells. PTEN deletion increased PI(3,4)P2 levels in a mouse model of prostate cancer, and it inversely correlated with PI(3,4)P2 levels across several EGF-stimulated prostate and breast cancer lines. These results point to a role for PI(3,4)P2 in the phenotype caused by loss-of-function mutations or deletions in PTEN. Display omitted •PTEN is a PI(3,4)P2 3-phosphatase•PTEN and INPP4B regulate PI(3,4)P2 accumulation downstream of class I PI3K•PTEN regulates PI(3,4)P2-dependent activation of Akt and formation of invadopodia•PI(3,4)P2 signaling may play a role in the tumor suppressor function of PTEN Malek et al. show that the tumor suppressor PTEN acts as a PI(3,4)P2 3-phosphatase within the growth factor-stimulated PI3K signaling network, in addition to its accepted role as a PI(3,4,5)P3 3-phosphatase. This suggests that specific PI(3,4)P2 effector functions, such as invadopodia formation, play a role in the PTEN-loss-of-function phenotype.